{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T19:00:46Z","timestamp":1778958046434,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.reuma.2015.12.005","type":"journal-article","created":{"date-parts":[[2016,1,30]],"date-time":"2016-01-30T06:31:23Z","timestamp":1454135483000},"page":"307-312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["\u00bfSe asocia la obesidad en la artritis psori\u00e1sica a una menor respuesta terap\u00e9utica y m\u00e1s efectos adversos con el tratamiento de fondo?"],"prefix":"10.1016","volume":"12","author":[{"given":"Eva","family":"Gal\u00edndez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loreto","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reuma.2015.12.005_bib0115","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/acr.22185","article-title":"Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis","volume":"66","author":"Labitigan","year":"2014","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.reuma.2015.12.005_bib0120","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3389\/fimmu.2014.00368","article-title":"Relationships between adipose tissue and psoriasis, with or without arthritis","volume":"5","author":"Toussirot","year":"2014","journal-title":"Front Immunol."},{"key":"10.1016\/j.reuma.2015.12.005_bib0125","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/archdermatol.2010.370","article-title":"Prevalence of the metabolic syndrome in psoriasis: Results from the National Health and Nutrition Examination Survey, 2003-2006","volume":"147","author":"Love","year":"2011","journal-title":"Arch Dermatol."},{"key":"10.1016\/j.reuma.2015.12.005_bib0130","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3899\/jrheum.140021","article-title":"High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease","volume":"41","author":"Haroon","year":"2014","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reuma.2015.12.005_bib0135","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/met.2013.0039","article-title":"Increased prevalence of metabolic syndrome in patients with psoriatic arthritis","volume":"12","author":"Pehlevan","year":"2014","journal-title":"Metab Syndr Relat Disord."},{"key":"10.1016\/j.reuma.2015.12.005_bib0140","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.autrev.2014.07.001","article-title":"Obesity in autoimmune diseases: Not a passive bystander","volume":"13","author":"Versini","year":"2014","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.reuma.2015.12.005_bib0145","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jaad.2009.11.012","article-title":"Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations","volume":"63","author":"Lebwohl","year":"2010","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.reuma.2015.12.005_bib0150","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jaad.2007.11.011","article-title":"The effect of weight on the efficacy of biologic therapy in patients with psoriasis","volume":"58","author":"Clark","year":"2008","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.reuma.2015.12.005_bib0155","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000156599","article-title":"Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis","volume":"217","author":"Naldi","year":"2008","journal-title":"Dermatology."},{"key":"10.1016\/j.reuma.2015.12.005_bib0160","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00394-013-0599-2","article-title":"TNFalpha blockade for inflammatory rheumatic diseases is associated with a significant gain in android fat mass and has varying effects on adipokines: a 2-year prospective study","volume":"53","author":"Toussirot","year":"2014","journal-title":"Eur J Clin Nutr."},{"key":"10.1016\/j.reuma.2015.12.005_bib0165","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA."},{"key":"10.1016\/j.reuma.2015.12.005_bib0170","first-page":"233","article-title":"Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: An exploratory analysis from the APHRODITE data","volume":"22","author":"Cassano","year":"2008","journal-title":"J Biol Regul Homeost Agents."},{"key":"10.1016\/j.reuma.2015.12.005_bib0175","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/acr.21711","article-title":"Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis","volume":"65","author":"Di Minno","year":"2013","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.reuma.2015.12.005_bib0180","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/annrheumdis-2012-202812","article-title":"Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor alpha blockers","volume":"73","author":"Di Minno","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2015.12.005_bib0185","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/annrheumdis-2013-204448","article-title":"Obesity is associated with lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis","volume":"74","author":"Eder","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2015.12.005_bib0190","first-page":"2595","article-title":"Effect of weight, body mass index and weight-based dosing on persistency of anti-TNFs in psoriatic arthritis","author":"Greenberg","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2015.12.005_bib0195","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1136\/annrheumdis-2013-eular.1998","article-title":"The characteristics and predictors of minimal disease activity in patients with psoriatic arthritis on TNF blockers","author":"Haddad","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2015.12.005_bib0200","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3109\/03009742.2012.715186","article-title":"Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-alpha therapy","volume":"42","author":"Iannone","year":"2013","journal-title":"Scand J Rheumatol."},{"issue":"Suppl 3","key":"10.1016\/j.reuma.2015.12.005_bib0205","first-page":"948","article-title":"Differences in disease characteristics of patients with active psoriatic arthritis prior to adalimumab treatment who failed at least two antiTNF-therapies in comparison to those who failed conventional DMARDS only","volume":"72","author":"Koehm","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2015.12.005_bib0210","first-page":"112","article-title":"[Liver diseases in rheumatoid and psoriatic arthritis]","volume":"42","author":"Santiago Garcia","year":"2012","journal-title":"Acta Gastroenterol Latinoam."},{"key":"10.1016\/j.reuma.2015.12.005_bib0215","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/acr.22294","article-title":"Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record","volume":"66","author":"Schmajuk","year":"2014","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.reuma.2015.12.005_bib0220","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3899\/jrheum.111391","article-title":"Hepatic steatosis and disease activity in subjects with psoriatic arthritis receiving tumor necrosis factor-alpha blockers","volume":"39","author":"Di Minno","year":"2012","journal-title":"J Rheumatol."}],"container-title":["Reumatolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X15002296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X15002296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T08:08:02Z","timestamp":1748765282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1699258X15002296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S1699258X15002296"],"URL":"https:\/\/doi.org\/10.1016\/j.reuma.2015.12.005","relation":{},"ISSN":["1699-258X"],"issn-type":[{"value":"1699-258X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u00bfSe asocia la obesidad en la artritis psori\u00e1sica a una menor respuesta terap\u00e9utica y m\u00e1s efectos adversos con el tratamiento de fondo?","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reuma.2015.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Reumatolog\u00eda y Colegio Mexicano de Reumatolog\u00eda. All rights reserved.","name":"copyright","label":"Copyright"}]}}